Swiss Medica, Inc.

Swiss Medica, Inc.

March 29, 2005 08:43 ET

Randomized Double Blind Clinical Study Shows Improvement for 90% of Fibromyalgia Patients Using Swiss Medica's O24 Pain Relief Product



OTC Bulletin Board SYMBOL: SWME

MARCH 29, 2005 - 08:43 ET

Randomized Double Blind Clinical Study Shows
Improvement for 90% of Fibromyalgia Patients Using
Swiss Medica's O24 Pain Relief Product

TORONTO, ONTARIO--(CCNMatthews - March 29, 2005) - Pursuant to the
Company's December 22nd (2004) News Release, Swiss Medica (OTCBB:SWME)
is pleased to announce the results of the randomized double blind
clinical trial conducted during the fourth quarter, comparing the
Company's O24 pain reliever against a placebo on patients suffering from

Dr. Gordon Ko (Head, Fibromyalgia clinic) and Dr. David Berbrayer (Head,
Dept. Rehabilitation Medicine) at Sunnybrook & Women's Health Sciences
Centre (University of Toronto), directed this 4-6 week pilot study of
153 fibromyalgia subjects. Of these, 133 participants (87%) completed
the study with 68 (51%) using a placebo. The other 65 (49%) used the O24
product. Assessments of these participants were carried out at multiple
community clinics in the Greater Toronto Area.

"The group treated with O24 compared to placebo showed statistically
significant improvement when measured on the Visual Analog Scale for
pain," announced Dr. Gordon Ko, who is also the Medical Director for the
Canadian Centre for Integrative Medicine in Markham, Ontario. Dr. Ko's
clinical study was statistically peer-reviewed by Marko Katic,
biostatistician at the Institute of Clinical Evaluative Studies (ICES).
Dr. Ko has submitted his findings to a peer-reviewed medical journal for

Improvement was also statistically significant for VAS night pain, Jamar
hand-grip strength, total number of fibromyalgia tender points and the
average tender point pain threshold as measured by algometry. For
participants who used O24, more than 90% of the patients reported mild
to markedly better improvement on the 7-point Lanier rating scale.
Nearly 54% reported moderately better or markedly better results using
O24 instead of the placebo. About 80% of the placebo group reported no
change in their condition and 13% reported a worsening of their
condition. Only 7% reported mild improvement from the placebo.

Dr. Ko concluded about O24, "With the demise of traditional medications,
such as the Cox-2 inhibitors, the use of therapies that have such
clinical effectiveness, and minimal to insignificant side effects, is
exciting news."

Swiss Medica's President, Grant Johnson announced, "This is a landmark
certification for Swiss Medica and a superlative confirmation for the
performance of the company's O24 product in reducing pain. With the
significant discovery that more than 90% of the patients who improved,
using our O24 pain relief product, compared to only 7% who experienced
mild improvement using the placebo, this clinical trial clearly confirms
that O24 provides an outstanding efficacy in pain management therapy.
Based upon these clinical results, we will move forward with our plans
to launch O24 Fibromyalgia in Q3 designed for those that suffer from
this serious condition. Our next phase will include a longer,
placebo-controlled crossover clinical study with a larger patient base
and multi-site studies, which we will announce at the appropriate time."

At present, there are no medications approved by the U.S. Food and Drug
Administration (FDA) for treating fibromyalgia, a common and chronic
disorder characterized by widespread muscle pain, fatigue, and multiple
tender points. According to the National Fibromyalgia Association, "It
is estimated that approximately 3-6% of the U.S. population has
fibromyalgia." Based upon the latest expert estimates, fibromyalgia may
affect between 8 million and 17 million Americans.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve
chronic ailments. We increase our market share through focused
distribution strategies in multiple sales channels. Swiss Medica's
mission is to be a world leader in the commercialization of life
enhancing bioscience products that improve quality of lives. Please
visit our websites at and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer,
holds US Patent #6,444,238B1. The O24 pain relief solution has been
used, recommended and praised for its fast-acting and long-lasting
benefits by healthcare professionals in the United States, Canada and in
Europe. O24 is widely available throughout Canada in leading pharmacies
and natural food stores. It is currently sold in an increasing number of
pharmacies throughout the United States. Customers can also visit, for ordering details and store locators for the nearest

Forward-looking statements in this news release are made pursuant to the
"Safe Harbor" provisions of the United States Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties, including,
without limitation, risks relating to the ability to close transactions
being contemplated, risks related to international sales and potential
foreign currency exchange fluctuations, continued acceptance of Swiss
Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks
detailed from time to time in Swiss Medica's periodic reports filed with
the United States Securities and Exchange Commission and other
regulatory authorities.


Contact Information

    Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    1 866 485 4243
    Blue Skye PR, Inc.
    Press Contact:
    Sky Wallen
    813 732 6869